Serial minimal residual disease (MRD) monitoring during first-line FCR treatment for CLL may direct individualized therapeutic strategies

Philip A. Thompson, Christine B. Peterson, Paolo Strati, Jeff Jorgensen, Michael J. Keating, Susan M. O’Brien, Alessandra Ferrajoli, Jan A. Burger, Zeev Estrov, Nitin Jain, Tapan M. Kadia, Gautam Borthakur, Courtney D. DiNardo, Naval Daver, Elias Jabbour, William G. Wierda

Research output: Contribution to journal › Article › peer-review

32 Scopus citations

Fingerprint

Dive into the research topics of 'Serial minimal residual disease (MRD) monitoring during first-line FCR treatment for CLL may direct individualized therapeutic strategies'. Together they form a unique fingerprint.

Medicine & Life Sciences